GAO And Legislators Pushing HHS For Stronger 340B Oversight
Executive SummaryThe Government Accountability Office is proposing several recommendations to strengthen oversight of the 340B drug discount program, but says the HHS Health Resources and Services Administration wants to take other measures that GAO believes are insufficient.
You may also be interested in...
HRSA has launched only one audit of a drug manufacturer for compliance with 340B drug pricing requirements, and that is still ongoing, but the agency plans additional audits in 2015.
Grassley suggests concern that the big pharmacy chain’s participation in the program may lead to diversion, in which drugs purchased at discounted 340B pricing are dispensed to insured individuals, allowing the pharmacy to profit from the difference in payments.
Top Republicans on two Senate health committees are joined by House members in seeking answers on an HHS review of entities receiving 340B drug discounts, including the process and consequences of audits and decertification.